Abstract
Background Vaccinations have reduced severe burden of COVID-19 and allowed for lifting of non-pharmaceutical interventions. However, with immunity waning alongside emergence of more transmissible variants of concern, vaccination strategies must be examined.
Methods Here we apply a SARS-CoV-2 transmission model to identify preferred frequency, timing, and target groups for vaccine boosters to minimise public health burden and health systems risk. We estimated new infections and hospital admissions averted over two-years through annual or biannual boosting of those eligible (those who received doses one and two) who are 1) most vulnerable (60+ or persons with comorbidities) or 2) those 5+, at universal (98% of eligible) or lower coverage (85% of those 50+ or with comorbidities and 50% of 5−49-year-olds who are eligible) representing moderate vaccine fatigue and/or hesitancy. We simulated three emerging variant scenarios: 1) no new variants; 2) 25% more infectious and immune-evading, Omicron-level severity, variants emerge annually and become dominant; and 3) emerge biannually. We further explored the impact of varying seasonality, variant severity, timing, immune evasion, and infectivity, and vaccine infection blocking assumptions.
Results To minimise COVID-19-related hospitalisations over the next two years, boosters should be provided for all those eligible annually three-four months ahead of peak winter whether or not new variants of concern emerge. Only boosting those most vulnerable is unlikely to ensure reduced stress on health systems. Moreover, boosting all eligible protects those most vulnerable more than only boosting the vulnerable group. Conversely, more hospitalisations could be averted per booster dose through annual boosting of those most vulnerable versus all eligible, an indication of cost-effectiveness. Whereas increasing to biannual boosting showed diminishing returns. Results were robust when key model parameters were varied. However, we found that the more frequently variants emerge, the less the effect boosters will have, regardless of whether administered annually or biannually.
Conclusions Well-timed and targeted vaccine boosters preferencing vulnerable, and if possible, all those eligible to receive boosters, can minimise infections and hospital admissions. Findings provide model-based evidence for decision-makers to plan for administering COVID-19 boosters ahead of winter 2022−2023 to help mitigate the health burden and health system stress.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for the study was provided by the Botnar Research Centre for Child Health (DZX2165 to MAP), the Swiss National Science Foundation Professorship of MAP (PP00P3_203450), and Swiss National Science Foundation NFP 78 Covid-19 2020 (4079P0_198428).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
No datasets were generated or analysed during this study. Data informing model parameters are described herein and in Shattock et al.6 Open-access model and figure code are available at https://github.com/SwissTPH/OpenCOVID. Data underpinning figures are available upon request.
